Literature DB >> 10488816

Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability.

P B Andersson1, E Waubant, L Gee, D E Goodkin.   

Abstract

OBJECTIVE: To use the new consensus definitions of primary progressive multiple sclerosis (PPMS) and progressive relapsing multiple sclerosis (PRMS) to report the demographic, clinical, and natural history characteristics of multiple sclerosis (MS) that is progressive from the time of onset.
DESIGN: Retrospective study by database/chart review and telephone interview.
SETTING: Multiple sclerosis clinic at a university teaching hospital. PATIENTS: Eighty-three patients (prevalence, 6.9%) with PPMS and 12 patients (prevalence, 1.0%) with PRMS were studied.
RESULTS: Fifty-nine percent of the patients with PPMS (n=49) and 67% of the patients with PRMS (n=8) were women. Mean +/- SD ages at the time of onset were 41.2 +/- 10.5 and 38.0 +/- 7.3 years, respectively; mean disease duration was 14.2 +/- 8.8 and 12.2 +/- 6.5 years, respectively. The initial symptoms involved leg weakness in 94% of the patients with PPMS (n = 78) and 100% of the patients with PRMS (n= 12). For the PPMS cohort, a syndrome consistent with isolated myelopathy was found in 36% of patients (n = 30) and arm weakness without leg weakness did not occur. Mean +/- SEM time of progression to a score of 6.0 on the Expanded Disability Status Scale was 10.2 +/- 1.0 years for patients with PPMS and 10.9 +/- 2.6 years for patients with PRMS.
CONCLUSIONS: The clinical characteristics and disability progression of these MS subtypes were indistinguishable, with the exception of 1 or 2 relapses in patients with PRMS that occurred 8 months to 9 years after the onset of symptoms. We see little reason to consider PPMS and PRMS separate clinical entities; however, whether they can be better distinguished by radiological, histopathological, or immunological markers of disease activity remains unknown.

Entities:  

Mesh:

Year:  1999        PMID: 10488816     DOI: 10.1001/archneur.56.9.1138

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls.

Authors:  Philip Brenner; Ellenor Mittendorfer-Rutz; Jussi Jokinen; Kristina Alexanderson; Jan Hillert; Petter Tinghög
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-05-11       Impact factor: 4.328

2.  1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Authors:  J Suhy; W D Rooney; D E Goodkin; A A Capizzano; B J Soher; A A Maudsley; E Waubant; P B Andersson; M W Weiner
Journal:  Mult Scler       Date:  2000-06       Impact factor: 6.312

3.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 4.  Multiple sclerosis: diagnosis and the management of acute relapses.

Authors:  S M Leary; B Porter; A J Thompson
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

5.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

6.  Mechanisms of normal appearing corpus callosum injury related to pericallosal T1 lesions in multiple sclerosis using directional diffusion tensor and 1H MRS imaging.

Authors:  J Oh; R G Henry; C Genain; S J Nelson; D Pelletier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

7.  Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Authors:  Jordana Hughes; Vilija Jokubaitis; Alessandra Lugaresi; Raymond Hupperts; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Francois Grand'Maison; Pierre Grammond; Patrizia Sola; Diana Ferraro; Cristina Ramo-Tello; Maria Trojano; Mark Slee; Vahid Shaygannejad; Cavit Boz; Jeanette Lechner-Scott; Vincent Van Pesch; Eugenio Pucci; Claudio Solaro; Freek Verheul; Murat Terzi; Franco Granella; Daniele Spitaleri; Raed Alroughani; Jae-Kwan Jun; Adam Fambiatos; Anneke Van der Walt; Helmut Butzkueven; Tomas Kalincik
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

8.  Progressive Onset Multiple Sclerosis: Demographic, Clinical and Laboratory Characteristics of Patients With and Without Relapses in the Course.

Authors:  Bahar Kaymakamzade; Ahmet Kasım Kiliç; Aslı Tuncer Kurne; Rana Karabudak
Journal:  Noro Psikiyatr Ars       Date:  2018-07-04       Impact factor: 1.339

9.  Disease modifying agents for multiple sclerosis.

Authors:  Olga Hilas; Priti N Patel; Sum Lam
Journal:  Open Neurol J       Date:  2010-05-26

Review 10.  Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.

Authors:  Jan-Patrick Stellmann; Anneke Neuhaus; Christian Lederer; Martin Daumer; Christoph Heesen
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.